The clinical efficacy of ezetimibe combined with enhanced external counterpulsation in the treatment of unstable angina patients
Zhang Li
Li Huawei
Wei Ruifang
Wang Hongbin
Abstract：Objective To investigate the effects of ezetimibe combined with enhanced external counterpulsation on the vascular endothelial function,lipid metabolism,cardiac function,and angina attacks in patients with unstable angina.Methods A total of 100 patients with unstable angina who were admitted to the Xingtai Central Hospital(Former Xingtai Third Hospital)from February 2023 to March 2024 were selected and randomly divided into the control group(conventional treatment pluse zetimibe,50 cases)and the observation group(conventional treatment pluse zetimibe combined with enhanced external counterpulsation,50 cases)using the random envelope method.The vascular endothelial function indicators(serum endothelin-1,thromboxane B2,vascular endothe-lial growth factor,etc.),the lipid metabolism indicators(serum triglycerides,total cholesterol,low-density lipoprotein cholesterol,high-density lipoprotein cholesterol,etc.),cardiac function indicators(left ventricular ejection fraction,stroke volume,etc.),and the condition of angina attacks and Seattle Angina Questionnaire scores were compared between the two groups before treatment and 2 weeks after treatment.Results After 2 weeks of treatment,the levels of endothelin-1((56.03±5.04)ng·L-1),thromboxane B2((127.56±10.24)ng·L-1),triglycerides((1.82±0.35)mmol·L-1),total cholesterol((3.40±0.75)mmol·L-1),low-density lipoprotein cholesterol((2.13±0.36)mmol·L-1),the frequency of angina attacks((6.24±1.55)times·week-1),and the duration of each attack((3.41±1.08 min·time-1)in the observation group were lower than those in the control group(endothelin-1:(61.44±5.49)ng·L-1,thromboxane B2:(141.88±9.87)ng·L-1,triglycerides:(2.01±0.42)mmol·L-1,total cholesterol:(4.21±0.88)mmol·L-1,low-density lipoprotein cho-lesterol:(2.40±0.42)mmol·L-1,frequency of angina attacks:(8.51±1.79)times·week-1,duration of each attack:(5.20±1.17)min·time-1)(t=5.133,7.120,2.457,4.954,3.451,6.779,7.949,all P<0.05).The vascular endothelial growth factor level((70.68±6.22)ng·L-1),high-density lipoprotein cholesterol level((1.63±0.21)mmol·L-1),left ventricular ejection fraction((56.27±5.12)%),stroke volume((73.44±5.77)mL·min-1),and Seattle Angina Questionnaire score((89.39±8.23)points)in the observation group were higher than those in the control group(vascular endothelial growth factor:(64.70±5.44)ng·L-1,high-density lipoprotein cholesterol:(1.42±0.22)mmol·L-1,left ventricular ejection fraction:(50.75±5.53)%,stroke volume:(67.26±5.47)mL·min-1,Seattle Angina Question-naire score:(83.52±7.82)points)(t=5.117,4.882,5.179,5.496,3.656,all P<0.05).Conclusion Ezetimibe combined with enhanced external counterpulsation can effectively improve the vascular endothelial function,lipid metabolism,and cardiac function of patients with unstable angina,alleviate angina attacks,and improve the quality of life,thus having good clinical application value.
Keywords：Unstable anginaEzetimibeEnhanced external counterpulsationVascular endothelial functionLipid metabolism
Publication Date：2025-08-25
Online Publishing Date：2025-09-01(First online date of this platform, not the publication date of the document)
Pages：5( 815-819 )